by Rod Raynovich | Jun 6, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Speculation in small cap biopharmaceutical stocks has peaked and we urged weeks ago to raise cash positions to 10-15%. The ASCO “sell on the news effect” has continued today with some high fliers off significantly: Exelixis (EXEL $8.95) is off 18% after...
by Rod Raynovich | Oct 22, 2010 | BIOgraph
GE announced the purchase of Clarient (CLRT) for $5/share or $580M, a 34% premium over Clarient’s previous closing price. Revenues forecasted for 2011 and 2012 are at $114M and $136M respectively, pricing the deal at a Price to Sales of 4.25 to 5X. Revenues for...
by Rod Raynovich | Sep 23, 2010 | BIOgraph
Within the “diagnostics and tools” track at the Rodman and Renshaw Conference here are two interesting genomics companies that presented. Rosetta Genomics Ltd. (ROSG, $1.25) ,Market Cap $21M, Sh.Out. 16.5M Rosetta is an Israeli Company focused in...
by Rod Raynovich | Jul 6, 2010 | 2023-24 Life Science Portfolios, BIOgraph
But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization,...
by Rod Raynovich | May 10, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and...
by Rod Raynovich | Feb 15, 2010 | BIOgraph
Complete Genomics 2/18/10 Molecular Diagnostics and Genomics “Powering large-scale human genome studies”. Private Company Summary Complete Genomics(CGI) provides high quality, affordable DNA sequencing for commercial- scale research of the...